Skip to main content Back to Top
Advertisement

6/24/2019

Iopromide Injection

Products Affected - Description

    • Ultravist injection, Bayer, 240 mg iodine/ mL, 100 mL vial, 1 count, NDC 50419-0342-10
    • Ultravist injection, Bayer, 300 mg iodine/ mL, 100 mL vial, 1 count, NDC 50419-0344-10
    • Ultravist injection, Bayer, 300 mg iodine/ mL, 125 mL vial, 1 count, NDC 50419-0344-12
    • Ultravist injection, Bayer, 300 mg iodine/ mL, 150 mL vial, 1 count, NDC 50419-0344-15
    • Ultravist injection, Bayer, 300 mg iodine/ mL, 50 mL vial, 1 count, NDC 50419-0344-05
    • Ultravist injection, Bayer, 370 mg iodine/ mL, 100 mL vial, 1 count, NDC 50419-0346-10
    • Ultravist injection, Bayer, 370 mg iodine/ mL, 150 mL vial, 1 count, NDC 50419-0346-15
    • Ultravist injection, Bayer, 370 mg iodine/ mL, 200 mL vial, 1 count, NDC 50419-0346-20
    • Ultravist injection, Bayer, 370 mg iodine/ mL, 50 mL vial, 1 count, NDC 50419-0346-05

Reason for the Shortage

    • Bayer did not provide a reason for the shortage. Ultravist is sold through McKesson Specialty.
    • Bayer is the sole supplier of iopromide injection.

Available Products

    • There are no presentations available

Estimated Resupply Dates

    • Bayer has all Ultravist presentations on back order and the company does not expect product to be released until 2020.

Updated

Created June 24, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.